NSJ Bioreagents

CD105 Antibody Overview

CD105 Antibody reagents target CD105, also known as Endoglin, a homodimeric membrane glycoprotein that acts as a co-receptor for transforming growth factor-beta (TGF-β). CD105 is highly expressed on vascular endothelial cells, activated monocytes, and certain mesenchymal stem cells. Its functions include regulating angiogenesis, vascular remodeling, and immune responses, making it a critical molecule at the crossroads of vascular biology and oncology.

Overexpression of CD105 is strongly associated with tumor angiogenesis in cancers such as breast, colorectal, and renal carcinomas. In addition, CD105 expression marks mesenchymal stem cell populations and is often used to identify progenitor cells in regenerative medicine. Because of these broad functions, the CD105 Antibody is a valuable tool in vascular biology, oncology, and stem cell research, while the Endoglin Antibody offers complementary use in diagnostics and translational applications.

Why Choose CD105 Antibodies from NSJ Bioreagents?

NSJ Bioreagents provides CD105 Antibodies validated for immunohistochemistry, flow cytometry, western blotting, immunofluorescence, and ELISA. Each CD105 Antibody is carefully validated for specificity, reproducibility, and performance across multiple assay types.

By choosing CD105 Antibodies from NSJ Bioreagents, researchers gain reagents optimized for clarity and consistency. Our antibodies deliver reliable staining in endothelial tissues, reproducible protein detection in lysates, and robust performance across research workflows. Comprehensive datasheets, validated controls, and optimized protocols ensure reproducibility in both laboratory and clinical settings.

Applications of CD105 Antibodies

The CD105 Antibody supports wide-ranging applications in vascular biology, oncology, and stem cell research.

1) Angiogenesis and Vascular Biology

CD105 Antibodies highlight expression on endothelial cells during angiogenesis.
The CD105 Antibody supports studies of vascular remodeling and hypoxia-driven responses.
Endoglin Antibody reagents provide tools for cardiovascular and vascular disease research.

2) Oncology and Tumor Angiogenesis

CD105 Antibodies detect upregulation in tumor vasculature of solid cancers.
The CD105 Antibody supports biomarker discovery for tumor progression and metastasis.
Endoglin Antibody reagents contribute to translational oncology studies.

3) Stem Cell and Regenerative Medicine

CD105 Antibodies mark mesenchymal stem cell populations.
The CD105 Antibody validates progenitor cells in tissue repair and organoid models.
Endoglin Antibody reagents support regenerative medicine and cellular therapy research.

4) Inflammation and Immune Regulation

CD105 Antibodies detect expression on activated monocytes and immune cells.
The CD105 Antibody supports research into TGF-β–mediated immune modulation.
Endoglin Antibody reagents clarify immune–vascular interactions.

5) Cardiovascular Disease

CD105 Antibodies highlight endothelial activation in atherosclerosis and vascular inflammation.
The CD105 Antibody supports studies into hypertension, heart failure, and vascular injury.
Endoglin Antibody reagents validate biomarkers for cardiovascular diagnostics.

6) Translational and Clinical Research

CD105 Antibodies are validated in biomarker-driven oncology and vascular studies.
The CD105 Antibody supports clinical trials of anti-angiogenic therapies.
Endoglin Antibody reagents ensure reproducibility in translational workflows.

Why Are CD105 Antibodies Important?

CD105 is a key regulator of angiogenesis, vascular remodeling, and stem cell biology. The CD105 Antibody equips scientists with validated reagents to study these processes, while the Endoglin Antibody expands applications into oncology, regenerative medicine, and clinical diagnostics.

In vascular biology, CD105 Antibodies reveal endothelial activation and angiogenic signaling. In oncology, the CD105 Antibody highlights tumor vasculature and metastatic potential. In stem cell biology, Endoglin Antibody reagents provide lineage markers for mesenchymal progenitors.

Clinically, CD105 expression is both a biomarker and therapeutic target. Reliable detection with CD105 Antibodies ensures translational relevance from discovery science to patient care.

Conclusion

CD105 (Endoglin) is a multifunctional co-receptor critical for angiogenesis, vascular biology, oncology, and stem cell research. The CD105 Antibody provides researchers and clinicians with validated reagents for detecting CD105 in tumor angiogenesis, vascular remodeling, and regenerative studies, while the Endoglin Antibody offers complementary diagnostic and translational support. By ensuring specificity and reproducibility, these antibodies remain indispensable for advancing biomedical science and improving patient outcomes.